CIBA-GEIGY's ESTRADERM (ESTRODIAL) TRANSDERMAL PATCH for treatment of menopausal symptoms was approved by FDA Sept. 10. The product is available in dosages of 0.05 mg and 0.1 mg to be applied twice weekly. Estraderm is Ciba-Geigy's third transdermal patch product utilizing Alza's delivery system. Ciba's Transderm Scop (scopolamine) was the first transdermal product on the market, followed by three nitroglycerin patches, of which Transderm-Nitro is the market leader. Estraderm is the third drug class to be made available in a transdermal delivery system. Boehringer Ingelheim's antihypertensive Catapres (clonidine) is the only other product line besides nitroglycerin. Ciba-Geigy obtained approval for Estraderm two years after an NDA submission in August 1984. FDA's Fertility and Maternal Health Drugs Advisory Cmte. recommended it for approval last December. The transdermal estrogen product is currently in clinicals for osteoporosis.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
